It is similar to LSD and is named for the propionyl group bound to the nitrogen of the polycyclic indole group of LSD. ġP-LSD is a semisynthetic compound of the lysergamide family.
Cooper, Future Synthetic Drugs of Abuse, 1988. Carrying this theme to the next logical step one would then assume that the 1-alkyl and 1-acyl derivatives of the N,N-dimethyl isomer would also not be controlled by the CsA amendment. clandestine chemist when he notes that lysergic acid amide is listed as a Schedule III substance in the CFR therefore, structurally similar substances of this compound are exempted from the CsA amendment.Ī lucid argument can then be made that lysergic acid N,N-dimethylamide is derived from lysergic acid amide rather than LSD. a reduction in hallucinogenic activity may become acceptable to the U.S. Interestingly, the future usage of 1-alkylated lysergamide derivatives as a means to bypass controlled substance laws banning LSD as a precursor was foreseen in a DEA report from 1988: Īlthough it was likely discovered in an academic setting, it is unknown who first synthesized 1P-LSD, as the substance does not appear in any academic literature pre-dating its arrival on the research chemical market. It is highly advised to use harm reduction practices if using this substance.ġP-LSD first appeared on the online research chemical market in January 2015. It is presumed to have a similar toxicity and risk profile as LSD, although there are no formal studies that prove this. Very little data exists about the pharmacological properties, metabolism, and toxicity of 1P-LSD. Its classical psychedelic effects and favorable tolerability has led it to become popular among novel substance users who use it interchangeably with LSD.
This predicts a near-identical effect profile, likely differing mainly in its rate of absorption and duration. This hypothesis is supported by the results of a study that demonstrated 1P-LSD is metabolized to LSD in rats. It is theorized to act as a prodrug for LSD. User reports indicate that the subjective effects of 1P-LSD are extremely similar to those of LSD. Subjective effects include geometric visual hallucinations, time distortion, enhanced introspection, conceptual thinking, euphoria, and ego loss. In 2019, it became part of a group of molecules studied by the French laboratory Caulredaitens. It was marketed as a legal alternative to LSD alongside other novel lysergamides like ALD-52, ETH-LAD, and AL-LAD. Unlike most research chemicals, it has no documented record in the research literature before its emergence on the online research chemical market in 2015.
It is thought to produce its effects by stimulating serotonin receptors in the brain, although the precise mechanism is not known.ġP-LSD has been sold online as a research chemical (also called "designer drug") since 2015, but the original synthesis date of 1P-LSD is unknown. It is structurally related to LSD and other novel lysergamides like 1cP-LSD, 1B-LSD, and 1V-LSD. It is not a recommendation and should be verified with other sources for accuracy.ġ-Propionyl- d-lysergic acid diethylamide (also known as 1P-LSD) is a novel psychedelic substance of the lysergamide class.
See responsible use section.ĭISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. (6aR,9R)-4-propionyl-N,N-Diethyl-7-methyl-4-propanoyl-6,6a,8,9-tetrahydroindoloquinoline-9-carboxamide